Sutro Biopharma (STRO) EPS (Weighted Average and Diluted) (2019 - 2025)
Historic EPS (Weighted Average and Diluted) for Sutro Biopharma (STRO) over the last 7 years, with Q3 2025 value amounting to -$0.67.
- Sutro Biopharma's EPS (Weighted Average and Diluted) fell 1355.93% to -$0.67 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.61, marking a year-over-year decrease of 6211.18%. This contributed to the annual value of -$2.96 for FY2024, which is 6635.32% down from last year.
- According to the latest figures from Q3 2025, Sutro Biopharma's EPS (Weighted Average and Diluted) is -$0.67, which was down 1355.93% from -$0.14 recorded in Q2 2025.
- In the past 5 years, Sutro Biopharma's EPS (Weighted Average and Diluted) registered a high of $0.52 during Q4 2023, and its lowest value of -$0.95 during Q1 2024.
- Moreover, its 5-year median value for EPS (Weighted Average and Diluted) was -$0.66 (2021), whereas its average is -$0.58.
- Per our database at Business Quant, Sutro Biopharma's EPS (Weighted Average and Diluted) crashed by 32307.69% in 2022 and then surged by 18524.59% in 2023.
- Quarter analysis of 5 years shows Sutro Biopharma's EPS (Weighted Average and Diluted) stood at -$0.83 in 2021, then grew by 26.51% to -$0.61 in 2022, then surged by 185.25% to $0.52 in 2023, then tumbled by 281.42% to -$0.94 in 2024, then rose by 28.98% to -$0.67 in 2025.
- Its last three reported values are -$0.67 in Q3 2025, -$0.14 for Q2 2025, and -$0.79 during Q1 2025.